Iridium oxide nanomonitors: clinical diagnostic devices for health monitoring systems

The objective of this research is to demonstrate the potential of iridium oxide (IrOx) nanowires based device towards detection of proteins that are disease biomarkers. This device is based on electrical detection of protein biomarkers wherein an immunoassay is built onto the iridium oxide nanowires that in turn undergoes specific electrical parameter perturbations during each binding event associated with the immunoassay. Detection of two inflammatory proteins C-reactive protein (CRP) and Myeloperoxidase (MPO) that are biomarkers of cardiovascular diseases is demonstrated. The performance metrics of the device in response to the two biomarkers in pure form and in serum samples were evaluated and compared to standard ELISA assays. The methodology that has been adopted is based on measuring impedance and calibrating its change in magnitude with concentration of proteins. We demonstrate the following performance metrics: limits of detection up to 1 ng/ml for CRP and 500 pg/ml for MPO in pure and serum samples; linear dynamic range of detection from 10 ng/ml to 100 microg/ml for CRP and 1 ng/ml to 1 microg/ml for MPO and cross-reactivity contained at less than 10% of selective binding for both the inflammatory proteins. Iridium oxide has an ability to detect very small changes to the surface charge and this capability is utilized for achieving the performance metrics and forms the basis of the key innovations of this technology, which are, improving the selectivity and sensitivity of detection.